The ensemble of genetic factors and angiogenic signals via VEGF receptors in lung cancer progression.
Lung cancer is the major cause of cancer-related mortality worldwide owing to its late-stage detection and aggressive behavior. Epidemiologically, several genetic and epigenetic factors contribute to the development of lung cancer. Angiogenesis, a critical process in tumor progression has become an important target for anti-cancer therapy particularly in lung cancer. Besides commercially available angiogenic inhibitors, numerous anti-angiogenic therapies have been developed to limit tumor growth, although, most of them have not proved beneficial in terms of long-term survival. Despite, logical advances in treatment strategies, NSCLC still remains a major health concern due to poor prognosis of the diseases state. This calls for a comprehensive analysis of signaling processes governing tumor angiogenesis and treatment options available thereof for development of a sustainable strategy to control cancer. In this review, several aspects of lung cancer have been discussed starting from its pathological characterization to the development of modern therapeutics.
['Danish|Qazi|Q|', 'Mokhdomi|Taseem A|TA|', 'Bukhari|Shoiab|S|', 'Ahmad|Raies|R|']
D020533:Angiogenesis Inhibitors D018450:Disease Progression D006801:Humans D008175:Lung Neoplasms D009389:Neovascularization, Pathologic D040262:Receptors, Vascular Endothelial Growth Factor D015398:Signal Transduction
VEGF receptors Lung cancer angiogenesis